Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate committee hears hours of testimony on clinician‑led psilocybin program bill
Summary
Senate Health and Long Term Care Committee heard extensive testimony for and against SB 5921, which would create a Department of Health‑regulated medical psilocybin program effective 07/01/2028; proponents cited clinical trial promise and veterans’ stories, while medical groups warned safeguards and workforce scope need tightening.
The Washington Senate Health and Long Term Care Committee on Jan. 27 heard hours of public testimony on Senate Bill 5921, a proposal to create a clinician‑led, Department of Health‑regulated medical psilocybin program.
Committee staff Jacob Ewing summarized the bill as establishing two license types — a producer license and a clinician participation license — and delegating to DOH the authority to set training, treatment and dosage standards, data‑collection requirements, and criminal‑history background checks via the Washington State Patrol and the FBI. The bill specifies that qualifying‑condition determinations would be made by the prescribing clinician and that the program would take effect on July 1, 2028.
Senator Jesse Solomon (32nd District), the prime sponsor, told the committee the bill follows a…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
